Granules India completes acquisition of Senn Chemicals

‘Senn’s specialised expertise in peptide development and its strong customer relationships complement Granules’ manufacturing strength and global reach’

Granules India has successfully closed previously announced acquisition of Senn Chemicals AG, a Swiss-based Contract Development and Manufacturing Organisation (CDMO), specialising in peptide development and manufacturing.

The Hyderabad-based company had earlier singed a definitive share purchase agreement in February 2025, , through its wholly-owned Indian subsidiary, Granules Peptides, to acquire 100 per cent of the equity of Senn Chemicals from the founding Senn family for ₹192.5 crore.

Founded over 60 years ago, Senn Chemicals has built a strong reputation as a specialist in Liquid-Phase Peptide Synthesis (LPPS) and Solid-Phase Peptide Synthesis (SPPS), serving innovators and brand owners across pharmaceutical, cosmetic, amino acid derivative (AAD), and theragnostic markets.

The Senn Chemicals brand and its operations in Dielsdorf, Switzerland, will operate under Granules’ ownership, with a commitment to maintaining the company’s scientific excellence and customer focus.

Pivotal step

“The acquisition of Senn Chemicals AG marks a pivotal step in Granules’ strategic evolution into a science and innovation-led organisation. By entering the rapidly growing peptide therapeutics segment and building on Senn’s specialised CDMO capabilities, we are well positioned to deliver high-quality, next-generation treatments,’‘ Krishna Prasad Chigurupati, Chairman & Managing Director, Granules India said in a release on Thursday.

Senn’s specialised expertise in peptide development and its strong customer relationships complement Granules’ manufacturing strength and global reach, he added.

The acquisition will enable Granules to accelerate development and manufacturing of GLP-1 receptor agonists and other peptide-based APIs, addressing the growing demand in antidiabetic, anti-obesity, and other next-generation therapeutic areas.

Granules and Senn have already initiated joint development activities in this space, with a broader peptide API pipeline planned. This transaction also marks Granules’ foray into the CDMO space, with Senn’s established CDMO business providing a strong platform for growth.

Published on April 10, 2025